403
Sorry!!
Error! We're sorry, but the page you were looking for doesn't exist.
Gynecology Collaboration And Licensing Agreement Trends Analysis Report 2025 Discover Top 25 Active Biopharma Companies In Gynecology
(MENAFN- GlobeNewsWire - Nasdaq) Dublin, June 25, 2025 (GLOBE NEWSWIRE) -- The "Gynecology Collaboration and Licensing Deals 2016-2025" report has been added to ResearchAndMarkets.com's offering.
Gynecology Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the gynecology deals entered into by the worlds leading biopharma companies.
Fully revised and updated, the report provides details of 150 gynecology deals from 2016 to 2025. The report provides access to deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.
Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.
This report contains a comprehensive listing of collaboration and licensing deals announced since 2016 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by companies and their partners.
The initial chapters of this report provide an orientation of gynecology dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in gynecology dealmaking.
Chapter 3 covers the financial deal terms for deals signed in the gynecology field with stage of development announced. Deals are listed and sectioned by headline value, upfront payment, milestone payment and royalty rates.
Chapter 4 provides a review of the top 25 most active biopharma companies in gynecology dealmaking. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.
Chapter 5 provides a comprehensive and detailed review of gynecology deals signed and announced since 2016 where a contract document is available. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive directory of gynecology deals listed by therapeutic target.
The report also includes numerous table and figures that illustrate the trends and activities in gynecology deal making since 2016.
In addition, a comprehensive deal directory is provided organized by company A-Z and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Gynecology Collaboration and Licensing Deals provides the reader with the following key benefits:
Gynecology Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the gynecology deals entered into by the worlds leading biopharma companies.
Fully revised and updated, the report provides details of 150 gynecology deals from 2016 to 2025. The report provides access to deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.
Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.
This report contains a comprehensive listing of collaboration and licensing deals announced since 2016 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by companies and their partners.
The initial chapters of this report provide an orientation of gynecology dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in gynecology dealmaking.
Chapter 3 covers the financial deal terms for deals signed in the gynecology field with stage of development announced. Deals are listed and sectioned by headline value, upfront payment, milestone payment and royalty rates.
Chapter 4 provides a review of the top 25 most active biopharma companies in gynecology dealmaking. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.
Chapter 5 provides a comprehensive and detailed review of gynecology deals signed and announced since 2016 where a contract document is available. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive directory of gynecology deals listed by therapeutic target.
The report also includes numerous table and figures that illustrate the trends and activities in gynecology deal making since 2016.
In addition, a comprehensive deal directory is provided organized by company A-Z and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Gynecology Collaboration and Licensing Deals provides the reader with the following key benefits:
- Understand deal trends since 2016 Browse gynecology collaboration and licensing deals Benchmark analysis - identify market value of transactions Financials terms - upfront, milestone, royalties Directory of deals by company A-Z, therapy focus and technology type Leading deals by value Most active dealmakers Identify assets and deal terms for each transaction Access contract documents - insights into deal structures Due diligence - assess suitability of your proposed deal terms for partner companies Save hundreds of hours of research time
Gynecology Collaboration and Licensing Deals includes:
- Trends in gynecology dealmaking in the biopharma industry Overview of collaboration and licensing deal structure Directory of gynecology deal records covering pharmaceutical and biotechnology The leading gynecology deals by value Most active gynecology licensing dealmakers
Analyzing contract agreements allows due diligence of:
- What are the precise rights granted or optioned? What is actually granted by the agreement to the partner company? What exclusivity is granted? What is the payment structure for the deal? How are sales and payments audited? What is the deal term? How are the key terms of the agreement defined? How are IPRs handled and owned? Who is responsible for commercialization? Who is responsible for development, supply, and manufacture? How is confidentiality and publication managed? How are disputes to be resolved? Under what conditions can the deal be terminated? What happens when there is a change of ownership? What sublicensing and subcontracting provisions have been agreed? Which boilerplate clauses does the company insist upon? Which boilerplate clauses appear to differ from partner to partner or deal type to deal type? Which jurisdiction does the company insist upon for agreement law?
Key Topics Covered:
Chapter 1 - Introduction
Chapter 2 - Trends in gynecology dealmaking
2.1. Introduction
2.2. Gynecology partnering over the years
2.3. Gynecology partnering by deal type
2.4. Gynecology partnering by industry sector
2.5. Gynecology partnering by stage of development
2.6. Gynecology partnering by technology type
2.7. Gynecology partnering by therapeutic indication
Chapter 3 - Financial deal terms for gynecology partnering
3.1. Introduction
3.2. Disclosed financials terms for gynecology partnering
3.3. Gynecology partnering headline values
3.4. Gynecology deal upfront payments
3.5. Gynecology deal milestone payments
3.6. Gynecology royalty rates
Chapter 4 - Leading gynecology deals and dealmakers
4.1. Introduction
4.2. Most active in gynecology partnering
4.3. List of most active dealmakers in gynecology
4.4. Top gynecology deals by value
Chapter 5 - Gynecology contract document directory
5.1. Introduction
5.2. Gynecology partnering deals where contract document available
Chapter 6 - Gynecology dealmaking by therapeutic target
6.1. Introduction
6.2. Deals by gynecology therapeutic target
Companies Featured
- 23andMe Aarhus University Abbott Laboratories Abbvie Accord Healthcare Acerus Ache AdaptivEndo Advaxis Adynxx AIMA Laboratories AIVF Allakos Allegheny Technologies Altavant Sciences Amag Pharmaceuticals American Dental Association Amring Pharmaceuticals AntibioTx ApolloBio Aptorum Group Ascend Therapeutics Asieris MediTech ASKA Pharmaceuticals Aspen Pharmacare Canada AstraZeneca Auransa Avion Pharmaceuticals Avomeen Bayer Besins Healthcare Bill and Melinda Gates Foundation Biofourmis BioGen Medical BioNano Genomics BioPep BioSyent Pharma BioVaxys Bloom Fertility BMV Medica Brigham and Women's Hospital California Cryobank Cancer Prevention and Research Institute of Texas Celmatix Chinese Academy of Sciences Chugai Pharmaceutical Cicero Diagnostics Co-Diagnostics Cocrystal Pharma Conceptions Reproductive Associates of Colorado Conduit Pharmaceuticals Consortia Health ConTipi Control Flo Medical Coriell Life Sciences Cosette Pharmaceuticals CR Pharma Dare Bioscience Department of Defense Dewpoint Therapeutics Duke University Easton Pharmaceuticals Egalet Embr Labs Emory University EndoCeutics Enzyvant Science Especificos Stendhal Eurofins LifeCodexx European Board and College of Obstetrics and Gynaecology European Wellness Biomedical Group Evidation Health Evofem Biosciences Evotec Evvy Exeltis Expedeon ExSeed Ferring Pharmaceuticals Flo Health Foresee Pharmaceuticals Fujifilm Irvine Scientific Fuji Pharma Gameto Gedeon Richter Genea Biomedx Genetiks Genome Medical Genomic Prediction German Cancer Research Center Gilead Sciences GOG Foundation Good Start Genetics Granata Bio Guided Therapeutics Gynica Halt Medical Hammock Pharmaceuticals Health Decisions Helix Helix BioPharma Highmark Health Hologic Hope Medicine Hyloris Pharmaceuticals IBSA Group iGenomix Igyxos Illumina Indegene Lifesystems InnerOptic Technology Innovative Health Diagnostics Inovio Pharmaceuticals Inserm Transfert INVO Bioscience Jiangsu Hansoh Pharmaceutical Jiangsu Hengrui Medicine Johns Hopkins University Joylux Karolinska Institute KinoPharma Knight Therapeutics LinKinVax LUCA Science Lumir Lab mAbXience Massachusetts General Hospital Mayne Pharma MD Anderson Cancer Center MDNA Life Sciences Medinova Meitheal Pharmaceuticals Menarini MenoGeniX Merck and Co Merck KGaA Microbix Biosystems MicroGenDX MilanaPharm Millendo Therapeutics Millicent Pharma Milu Labs Mithra Pharmaceuticals Morphic Therapeutic Mundipharma MyBiotics Pharma Mycovia Pharmaceuticals Myovant Sciences Nanjing King-friend Biochemical Pharmaceutical National Human Genome Research Institute National Institute of Child Health and Human Development National Institute on Aging National Institutes of Health Novan NuProbe NX Prenatal ObsEva OmniVision Technologies OncoNano Medicine One Drop Osel Osivax Osteolabs Ovation Oviva Therapeutics OvuSense Palatin Technologies PaxGenBio PDS Biotechnology Pearsanta Pfizer PharmaJet Pharmanest Phase Genomics Photocure ASA Pierre Fabre PolarisQB Predictive Technology Group Procare Health Psyche Systems Purna Pharmaceuticals QIAGEN Radius Health Rebiotix ReproCell Roivant Sciences Royal Philips Electronics Scholar Rock Searchlight Pharma Selexis Sema4 Shandong Yaohua Medical Instrument Shenghuo Medical Skive Hospital Starpharma Statens Serum Institute St George Street Capital Strainprint Technologies Sumitomo Dainippon Pharma Sumitovant Biopharma Sun Pharmaceutical Syneos Health SynteractHCR Systems Oncology Takeda Pharmaceutical Tessa Therapeutics Texas A&M University Theramex TherapeuticsMD Thermo Fisher Scientific TiumBio TMRW Life Sciences Transgene twoXAR Ulisse Biomed University of Antwerp University of Illinois University of Leuven University of Oxford UpScriptHealth Urovant Sciences Vaccibody Valeo Pharma Veritas Viatris VICHY Laboratoires Viramal VirtaMed Vitro Biopharma Woom Xbrane Biopharma Xisle Pharma Ventures Trust
For more information about this report visit
About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
CONTACT: CONTACT: Laura Wood,Senior Press Manager ... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Most popular stories
Market Research
More Story
Comments
No comment